{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T11:02:25Z","timestamp":1793790145534,"version":"4.6.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. Novel biologic agents represent a potential therapeutic option. We explore the use of dupilumab in the treatment of BP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Relevant studies published up to Oct. 20th, 2025 were systematically searched using PubMed, Web of Science, Embase, and Cochrane Library. Proportion rates of complete response and disease control were analyzed to determine treatment effects. Data were quantitatively synthesized using a random-effects meta-analysis. Meanwhile, we also conducted statistics on adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 587 patients from 24 studies were included. Pooled analysis revealed a complete response rate of 68% (95% CI 60%\u223c78%) and disease control rate of 95% (95%CI 92%~98%) in BP treated with dupilumab with\/without other systemic therapy. Notably, complete response rate achieved 63% (95% CI 49%\u223c81%) in patients with dupilumab without other systemic therapy. A total of 112 adverse events were reported in 97 patients. Most adverse events were mild and did not lead to treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis highlights the efficacy and safety of dupilumab in patients with BP, offering valuable evidence to guide future clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420251048550.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1651543","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:22:29Z","timestamp":1770355349000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Dupilumab treatment outcomes in bullous pemphigoid: a systematic review and single-arm meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yudi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailv","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: a systematic review and meta-analysis","volume":"186","author":"Persson","year":"2022","journal-title":"Br J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1038\/s41467-024-50283-3","article-title":"Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.007","article-title":"Overexpression of helper T cell type 2-related molecules in the skin of patients with eosinophilic dermatosis of hematologic Malignancy","volume":"87","author":"Maglie","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15111","article-title":"Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)","volume":"46","author":"Ujiie","year":"2019","journal-title":"J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.35541\/cjd.20240622","article-title":"Diagnosis and treatment of bullous pemphigoid: an expert consensus statement (2025 edition)","volume":"58","author":"Zuo","year":"2025","journal-title":"Chin J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.04.075","article-title":"The treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors with biologic therapy: A single-institution retrospective study at a tertiary care cancer center","volume":"93","author":"Greenberg","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25259\/IJDVL_579_2025","article-title":"Efficacy and safety of dupilumab in Chinese patients aged over 60 years with bullous pemphigoid and comorbidities","volume":"12","author":"Jin","year":"2025","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111157","article-title":"Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study","volume":"125","author":"Huang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2024.04.012","article-title":"Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid","volume":"100","author":"Liang","year":"2025","journal-title":"Bras Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.36468\/pharmaceutical-sciences.spl.798","article-title":"Clinical efficacy of dupilumab injection in combination with systemic low-dose hormones in the treatment of bullous pemphigoid","volume":"85","author":"Bin","year":"2023","journal-title":"Indian J Pharm Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02362-y","article-title":"Overview of use, efficacy, and safety of dupilumab in complex patients: a retrospective, case-series study from a large, urban academic center","volume":"315","author":"Lukac","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e15648","DOI":"10.1111\/dth.15648","article-title":"Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.001","article-title":"A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes","volume":"87","author":"Bur","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/dth\/2257832","article-title":"Dupilumab as a therapeutic option in autoimmune bullous diseases following SARS-CoV-2 infection and COVID-19 vaccination: a comprehensive case series analysis","volume":"12","author":"Svara","year":"2025","journal-title":"Dermatol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdcr.2023.09.041","article-title":"The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study","volume":"2","author":"Young","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1157250","article-title":"Biological treatment for bullous pemphigoid","volume":"14","author":"Oren-Shabtai","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1208418","article-title":"Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience","volume":"20","author":"Merli","year":"2023","journal-title":"Front Med (Laus)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.4190","article-title":"Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients","volume":"31","author":"Liu","year":"2021","journal-title":"Eur J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06548-4","article-title":"Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients","volume":"30","author":"Lo","year":"2022","journal-title":"Support Care Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3881\/j.issn.1000-503X.16239","article-title":"Clinical features of chinese patients with bullous pemphigoid induced by immune checkpoint inhibitors","volume":"46","author":"Li","year":"2024","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae403","article-title":"Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series","volume":"192","author":"Planella-Fontanillas","year":"2025","journal-title":"Br J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e924","DOI":"10.1002\/iid3.924","article-title":"Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study","volume":"11","author":"Hu","year":"2023","journal-title":"Immun Inflammation Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1165106","article-title":"Anti-interleukin 4 receptor \u03b1 antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16525","article-title":"Dupilumab as a novel therapy for bullous pemphigoid","volume":"62","author":"Zhang","year":"2023","journal-title":"Int J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17999","article-title":"Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study","volume":"36","author":"Velin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1115083","article-title":"Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: A systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2022.09.001","article-title":"Biologic treatment outcomes in refractory bullous pemphigoid: An evidence-based review","volume":"9","author":"Abduelmula","year":"2022","journal-title":"JAAD Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2024.08.008","article-title":"Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis","volume":"100","author":"J\u00falia Opolski","year":"2025","journal-title":"Bras Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","article-title":"Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell","year":"2024","journal-title":"Adv Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1651543\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:22:31Z","timestamp":1770355351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1651543\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1651543"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1651543","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"article-number":"1651543"}}